Autophagy Modulation in Cancer Therapy: Navigating the Dual Roles to Overcome Chemoresistance Authors: Md Mohiuddin, Md Al Mamun Ahsan Published: 2026 ABSTRACT ABSTRACTBackgroundAutophagy is a fundamental cellular recycling mechanism with complex and often opposing roles in cancer, functioning as both a tumor suppressor and a pro‐survival mechanism in established tumors. This duality has attracted considerable attention, particularly regarding the therapeutic modulation of autophagy to overcome chemoresistance, a major challenge in cancer treatment. However, the function of autophagy is highly context‐dependent and varies with tumor stage, cellular subpopulations, and the tumor microenvironment (TME).DiscussionThis perspective examines the multifaceted role of autophagy in cancer, its therapeutic modulation to enhance chemosensitivity, the molecular pathways that regulate autophagy, and the current status of clinical trials with autophagy‐targeting agents. We critically discuss the limitations of first‐generation autophagy inhibitors, including hydroxychloroquine (HCQ) and chloroquine (CQ). Although these agents show chemosensitizing effects in some preclinical studies and have been evaluated clinically, they lack specificity and may cause off‐target toxicities. Particular emphasis is placed on the emerging understanding of selective autophagy pathways, such as mitophagy and ER‐phagy, and their context‐dependent impact on therapeutic outcomes. We further highlight that successful autophagy‐targeted therapy requires a nuanced, precision‐based approach that accounts for tumor heterogeneity and microenvironmental influences and integrates advanced drug delivery strategies, including nanomedicine, to achieve spatiotemporal control of autophagy.ConclusionTargeting autophagy represents a promising yet highly complex strategy for overcoming chemoresistance and requires a transition from global autophagy modulation to selective, context‐specific interventions. Future research should focus on developing highly selective autophagy modulators, identifying robust predictive biomarkers, and integrating precision nanomedicine approaches to safely manage autophagy's dual roles and optimize therapeutic outcomes across diverse tumor contexts.Keywords: autophagy, autophagy inhibitors, autophagy modulation, Cancer chemosensitization, chemoresistance, tumor microenvironment Introduction Cancer remains a major global public health issue, and resistance to traditional therapies (i.e., chemotherapies) is a substantial contributor to clinical failure and disease relapse [1, 2]. Autophagy is an evolutionarily conserved lysosomal degradation pathway that is vital for basic cellular functions, cellular integrity, and cellular homeostasis as it recycles cellular material [3, 4]. In cancer, autophagy is paradoxical; it can hinder tumor development by degrading damaged organelles and proteins but can also support the growth and survival of established tumor cells, especially under therapy‐induced stress [5, 6]. This dual characteristic suggests the potential of autophagy as a major therapeutic target in oncology. The rationale for targeting autophagy in cancer therapy stems from the discovery that cancer cells often undergo autophagy as a metabolic adaptation to survive the cytotoxicity of anticancer drugs [5]. Therefore, hindering this cytoprotective response can potentially lead to increased protein degradation, sensitizing cancer cells to existing treatments, thereby inducing more robust anticancer effects and overcoming resistance [5, 7]. Conversely, in early tumorigenesis, basal autophagy contributes to tumor suppression by maintaining cellular homeostasis, limiting oxidative stress, and preventing the accumulation of damaged organelles and oncogenic protein aggregates [8, 9]. This perspective article proposes a conceptual framework for navigating these context‐dependent dual roles of autophagy, emphasizing the need for critical interpretation and precise therapeutic strategies. We will outline an approach that addresses when to inhibit or activate autophagy, and how to selectively modulate specific autophagic pathways, to enhance chemosensitivity and improve patient outcomes. Autophagy and Enhanced Chemosensitivity Chemoresistance is a key obstacle to successful cancer treatment as it results in treatment failure and relapse [10]. Autophagy often acts as a cytoprotective mechanism in cancer cells, allowing them to avoid the cytotoxicity of chemotherapeutics [5, 11]. Therefore, inhibiting autophagy represents a promising approach for enhancing the sensitivity of cancer cells to various chemotherapeutic agents [11]. By blocking the stress‐adaptive autophagy response, cancer cells become more vulnerable to drug‐induced damage [12]. For example, the inhibition of autophagy with 3‐methyladenine (3‐MA) increases cisplatin‐induced apoptosis in U251 human glioma cells [13]. Moreover, combining autophagy inhibitors with conventional chemotherapy can yield a synergistic approach that enhances cancer cell death [5, 14]. This effect has been reported in multiple preclinical models and remains under evaluation in ongoing clinical trials [5, 14]. Furthermore, certain compounds, such as sulforaphane combined with cisplatin, can induce apoptosis in malignant mesothelioma cells, and autophagy inhibition further enhances this effect [15]. However, the role of autophagy in chemoresistance is highly context dependent, and autophagy inhibition should not be considered a universally effective strategy for enhancing chemosensitivity [16]. Tumor heterogeneity, cancer stage, genetic background, and metabolic conditions can influence whether autophagy promotes tumor survival or suppresses tumor progression [17, 18]. During early tumorigenesis, basal autophagy may function as a tumor suppressor by maintaining cellular homeostasis and limiting genomic instability [19, 20]. In contrast, in established tumors exposed to metabolic or therapeutic stress, sustained autophagy can support cancer cell survival and therapeutic resistance [21, 22]. Moreover, excessive activation of autophagy may, in some contexts, promote autophagic cell death and enhance chemosensitivity [23, 24]. Therefore, a context‐specific framework is required to determine when autophagy inhibition may be beneficial, ineffective, or potentially detrimental, and when autophagy activation could provide therapeutic advantages. Molecular Regulation of Autophagy in Cancer Cells Regulation of autophagy in cancer cells involves pathways that are often dysregulated, thereby favoring tumor survival, proliferation, and resistance to apoptosis [25]. Understanding these pathways is critical for developing targeted therapeutics. The mammalian target of rapamycin (mTOR) pathway acts as a central negative regulator of autophagy [26]. When the mTOR pathway is activated, autophagy is inhibited [26], whereas mTOR inhibition often induces autophagy [26, 27]. In gastric cancer cells, bufalin induces autophagy formation by inhibiting mTOR and activating extracellular signal‐regulated kinase 1/2 (ERK1/2) [28]. Beclin‐1 is another pivotal regulator of autophagy and a core component of the Vps34 kinase complex required for autophagosome formation [29, 30]. Functionally, its activity is often modulated by interactions with proteins such as Bcl‐2, whose dissociation can trigger autophagy [31]. The liver kinase B1 (LKB1)‐AMP‐activated protein kinase (AMPK) signaling pathway senses and regulates cellular energy availability [32, 33]. Under starvation or energy‐deprived conditions, AMPK is activated and subsequently induces autophagy, whereas under energy‐rich conditions, the growth‐promoting kinase mechanistic target of rapamycin complex 1 (mTORC1) is activated and inhibits autophagy [34]. The tumor suppressor p53 can similarly induce or inhibit autophagy depending on its cellular context [35]. The nuclear factor kappa‐B (NF‐κB) pathway can also be closely linked to autophagy, sharing common regulators and feedback loops that govern tumorigenesis and therapeutic responses [36]. MicroRNAs (miRNAs) play an instrumental role in regulating autophagy by targeting the mRNAs of essential autophagy‐related genes (ATGs) [37, 38, 39]. For example, miR‐30a sensitizes tumor cells to cisplatin (cis‐DDP) by inhibiting Beclin 1‐dependent autophagy [40] and miR‐1 increases cisplatin sensitivity by inhibiting ATG3‐dependent autophagy [41]. Other miRNAs such as miR‐101 and miR‐193b regulate autophagy and chemosensitivity in several cancers [42]. In addition to these pathways, numerous ATGs are involved in different phases of autophagy, from vesicle nucleation to fusion and degradation [43, 44]. Autophagy can also be regulated at several levels, including transcriptional gene networks, transcription factors such as the microphthalmia/transcription factor E (MiT/TFE) family, and epigenetic modifications [45, 46]. Heparanase, for example, not only influences signaling pathways that control gene expression levels and cellular behaviors, but can also regulate autophagy in cancer [47]. Autophagic flux regulation and selective autophagy pathways play critical roles in cancer progression and therapeutic response. Autophagic flux, which encompasses the dynamic processes of autophagosome formation, cargo degradation, and lysosomal reformation, is a key indicator of autophagic activity [48, 49]. Elevated autophagic flux can paradoxically promote cancer cell invasion and is associated with advanced tumor stages and reduced patient survival in several cancers [6]. For example, cancer cells located at the invasive front of human primary non‐small cell lung cancer tissues display higher autophagic flux than cells within the tumor core [50]. This increased flux is required for cell invasion and may even be sufficient in the absence of stromal cell interaction [50, 51]. Therefore, modulation of autophagic flux, rather than simple inhibition of autophagy initiation, may be essential for achieving therapeutic efficacy [52, 53]. Selective autophagy represents a more refined process that targets specific cellular components, including damaged organelles, misfolded proteins, and pathogens, for degradation [54, 55]. This process is essential for maintaining cellular homeostasis and preventing the accumulation of harmful cellular components [56]. Among the different forms of selective autophagy, mitophagy specifically targets damaged or excess mitochondria for degradation and plays an important role in cancer cell metabolism, survival, and therapy resistance [57, 58]. Mitophagy can support cancer progression by supplying nutrients and energy, maintaining the stem‐like properties of cancer stem cells, promoting invasion and metastasis, and mediating drug resistance [59, 60]. In contrast, basal mitophagy may function as a tumor‐suppressive mechanism by reducing damaged cellular components and limiting reactive oxygen species production [61, 62]. Another important selective autophagy pathway is ER‐phagy, which targets specific portions of the endoplasmic reticulum for degradation and is essential for preserving ER integrity and function [63, 64]. ER‐phagy can support cancer progression by alleviating ER stress and promoting cancer cell proliferation and survival [65, 66]. However, excessive ER‐phagy may also induce cancer cell death, highlighting its context‐dependent dual role in cancer biology [66, 67]. Several receptors, including FAM134B, RTN3L, and TEX264, serve as key mediators of this pathway [68]. Collectively, these regulatory mechanisms demonstrate that autophagy functions as an integrated and highly context‐dependent adaptive network rather than a single linear pathway [69, 70, 71]. Canonical regulators such as mTOR, AMPK, p53, and miRNA‐mediated signaling govern the initiation and magnitude of autophagy, whereas autophagic flux determines the efficiency of cargo degradation and recycling [72, 73, 74, 75, 76, 77]. Simultaneously, selective autophagy pathways, including mitophagy and ER‐phagy, enable cancer cells to adapt to metabolic stress, organelle damage, and therapy‐induced cellular stress [64, 78]. The interplay among these regulatory layers ultimately influences whether autophagy promotes tumor survival and chemoresistance or contributes to cellular damage and therapeutic response [71, 79]. Consequently, effective autophagy‐targeted therapies will likely require context‐specific strategies, in which global autophagy inhibition, selective modulation of specific autophagy pathways, or controlled autophagy activation are optimized according to tumor biology, disease stage, and treatment context. Clinical Trials of Autophagy Inhibitors Many clinical trials are exploring therapeutic options targeting autophagy in cancer, focusing on repurposing existing drugs and developing new and more specific agents [80, 81]. Chloroquine (CQ) and hydroxychloroquine (HCQ) are the most studied autophagy inhibitors in clinical trials [82, 83]. They predominantly function by inhibiting lysosomal acidification and autophagic degradation [84, 85]. They are most often studied in combination with standard anticancer treatments including chemotherapy, radiation, and targeted therapies [86, 87]. Some studies have focused on HCQ combined with gemcitabine or doxorubicin and CQ combined with temozolomide and radiation [82, 88, 89]. A meta‐analysis of seven clinical trials involving 293 patients revealed that therapy with an autophagy inhibitor led to improved treatment responses, including a higher overall response rate (ORR), 6‐month progression‐free survival (PFS), and 1‐year overall survival (OS) relative to therapy without autophagy inhibition [82]. Although the reported clinical outcomes appear encouraging, the available evidence remains limited by several important factors, including substantial heterogeneity among studies, relatively small patient cohorts, variability in tumor types, and differences in treatment regimens and study designs. Moreover, the context‐dependent role of autophagy in cancer further complicates the interpretation of these findings, as autophagy may exert either tumor‐promoting or tumor‐suppressive effects depending on tumor type, disease stage, metabolic state, and therapeutic context [16, 90]. Consequently, current clinical evidence should not be considered definitive validation of autophagy inhibition as a universally effective therapeutic strategy, but rather as support for a still evolving and potentially context‐specific therapeutic approach. In addition, CQ and HCQ lack selectivity and sufficient potency, raising concerns regarding off‐target effects and incomplete inhibition of autophagy at clinically achievable concentrations [91, 92, 93]. For example, prolonged HCQ use has been associated with retinopathy, with reported incidence rates reaching approximately 7.5% [94]. The limited therapeutic use of CQ and HCQ has led to the discovery of new, potent, and selective inhibitors [95, 96]. Lys05, a bisaminoquinoline derivative, is a more potent autophagy inhibitor than HCQ [97] and has demonstrated impressive single‐agent antitumor activity in preclinical models without toxicity at lower doses, warranting further clinical development [97]. In addition to lysosomal inhibitors, inhibitors of key autophagy kinases, such as Unc‐51‐like kinase 1 (ULK1) and vacuolar protein sorting 34 (Vps34), have been studied [98, 99]. High‐throughput screening platforms that identify and optimize small molecules that specifically modulate protein interactions within the autophagy machinery are used to identify selective inhibitors [100, 101]. Potential Side Effects of Modulating Autophagy While targeting autophagy is a promising and emerging approach in cancer treatment, potential side effects are a concern, given its critical role in maintaining homeostasis across many organs and cell types [102, 103]. Autophagy plays a protective role against acute kidney injury [104]. The inhibition of autophagy during cisplatin chemotherapy tends to exacerbate acute kidney injury, as autophagy typically provides a protective mechanism in renal tubular cells by eliminating damaged mitochondria and proteins [105]. Autophagy is important for neuronal and glial cell functions, and its disruption has been associated with various neurological diseases [106]. It is also vital for liver and heart health [107, 108], and the modulation of autophagy may induce damage to these organs, especially when combined with other cytotoxic agents [109, 110]. Hematopoietic stem cells depend on autophagy for their activity and are susceptible to other disruptions when autophagy is inhibited [111]. HCQ is widely known to cause retinopathy, with an incidence as high as 7.5%, with advanced diagnostic techniques [94, 112]. Current autophagy inhibitors are not specific, meaning that both cancerous and healthy cells are affected, potentially leading to off‐target effects [53]. While some studies have reported that autophagy inhibitors may introduce minor additive toxicity with certain chemotherapeutics, the full spectrum of their combined side effects remains to be investigated [113, 114]. A previous study also reported dose‐limiting fatigue and gastrointestinal effects in clinical trials [115]. The dual role of autophagy (pro‐survival vs. pro‐death), even in the context of cancer, means that inhibition may not always be beneficial and could even be harmful depending on the specific cancer context [116, 117]. Additionally, autophagy inhibitors may affect immune responses, potentially leading to adverse events in patients, especially when combined with immunotherapy [118]. Future Directions The field of autophagy modulation for cancer therapy is rapidly advancing, with several promising areas of future research poised for clinical translation [119, 120]. To effectively address the dual roles of autophagy in cancer, future therapeutic strategies should emphasize context‐dependent, selective modulation rather than relying solely on broad inhibition of autophagy. There is an urgent need to develop highly selective and potent autophagy modulators that specifically target components of the autophagic machinery, such as ULK1, Vps34, and specific autophagy‐related gene (ATG) interactions [99, 121, 122]. These selective modulators may reduce off‐target effects and systemic toxicities while improving therapeutic precision. Enhanced pharmacokinetic properties, including improved solubility, stability, and tumor penetration, may further increase efficacy. Concurrently, identifying reliable biomarkers that predict patient responses to autophagy modulation is crucial [123]. Genetic markers, including specific cancer genotypes, and phenotypic markers within the tumor microenvironment (TME) may serve as important predictive biomarkers [69, 123, 124]. Genome sequencing and phenotypic characterization could therefore help stratify patients who are most likely to benefit from therapies modulating autophagy, thereby optimizing clinical trial design and improving treatment outcomes [125, 126, 127]. Future research should also place greater emphasis on selective autophagy pathways, including mitophagy, ER‐phagy, lipophagy, and ferritinophagy, which may differentially regulate tumor survival, metabolic adaptation, oxidative stress, immune evasion, and therapy response [61, 128]. In some cancer contexts, preserving or selectively activating specific autophagy pathways may be beneficial for maintaining cellular homeostasis, reducing genomic instability, or enhancing antitumor immune responses [16, 61, 78]. Conversely, selective inhibition of these pathways may sensitize tumors to therapy by disrupting adaptive stress‐response mechanisms. For example, modulating mitophagy may have context‐specific therapeutic implications [129]. Enhancing mitophagy could facilitate the clearance of damaged mitochondria, thereby reducing oxidative stress and limiting tumor progression in certain settings [130, 131]. In contrast, inhibiting mitophagy may promote the accumulation of dysfunctional mitochondria and sensitize cancer cells to chemotherapy or targeted therapies [132, 133]. Similarly, tailored manipulation of ER‐phagy may either alleviate ER stress‐associated tumor adaptation or induce excessive ER stress and cell death depending on the biological context [67, 134]. Future studies should rationally design combination therapies that exploit the synergistic effects of autophagy modulation with existing anticancer agents, including chemotherapy, radiotherapy, targeted therapies, and immunotherapies [120, 135, 136, 137, 138, 139, 140]. Determining the optimal timing and dosing schedules for combining autophagy modulators with these regimens will be critical for maximizing therapeutic efficacy while minimizing toxicity [14, 127, 141]. Strategies to overcome the acidic TME, such as pH‐sensitive drug delivery systems, may further enhance the effects of lysosomotropic agents such as CQ and HCQ [85]. Furthermore, nanocarriers offer a compelling approach for targeted delivery of autophagy modulators to tumors, potentially overcoming resistance, reducing systemic toxicity, and improving drug efficacy [138, 142]. Additional detailed studies are needed to precisely define the context‐dependent role of autophagy across different cancer types and stages [90, 143]. This includes determining whether autophagy predominantly promotes tumor survival or contributes to cell death under specific biological and therapeutic conditions. Examining how cancer cells adapt to autophagy modulation over time will also help clarify strategies to prevent or overcome acquired therapeutic resistance [103, 144]. Table 1 summarizes the context‐dependent roles of autophagy in cancer progression and therapeutic response, with particular emphasis on unresolved mechanistic questions, translational challenges, biomarker‐guided patient stratification, and emerging future directions for precision autophagy‐targeted interventions. Table 1Context‐dependent roles of autophagy in cancer and implications for precision therapeutic stratification.Role in cancerEstablished evidenceContext‐dependent mechanismTherapeutic implications and future directionsTumor suppressorAutophagy reduces the accumulation of damaged proteins and organelles, thereby limiting cellular stress, genomic instability, and mutational burden [18, 145, 146]. It also contributes to immune surveillance during early tumorigenesis [147].Early‐stage tumors and basal physiological conditions: autophagy maintains cellular homeostasis, suppresses oxidative stress, and prevents malignant transformation [18, 148, 149].Future strategies should investigate selective autophagy activation for cancer prevention or for tumors with impaired basal autophagy [61]. Targeting selective processes such as mitophagy may improve clearance of damaged cellular components while minimizing systemic toxicity [150, 151]. A major unresolved challenge is identifying the precise conditions under which autophagy activation remains protective in humans [23, 152, 153].Tumor promoter/pro‐survivalEstablished tumors exploit autophagy to maintain metabolic adaptation, survive hypoxia and nutrient deprivation, and resist therapy‐induced stress [145, 154]. Increased autophagic flux is frequently associated with tumor progression and therapeutic resistance [78, 155].Advanced tumors under metabolic stress, hypoxia, or therapeutic pressure: autophagy supports tumor survival, immune evasion, invasion, and chemoresistance [78, 156, 157]. Elevated autophagic activity in invasive tumor cells is often associated with poor prognosis [50, 78].Future therapeutic strategies should prioritize selective autophagy inhibitors targeting context‐specific pathways, including late‐stage autophagic flux, mitophagy, or ER‐phagy [61, 152]. Identification of predictive biomarkers for autophagy dependence will be critical for patient stratification and precision therapy [16, 64]. Key translational challenges include minimizing off‐target toxicity and preserving autophagic function in normal tissues [16, 158]. Context‐dependent roles of autophagy in cancer and implications for precision therapeutic stratification. Conclusion Autophagy is a highly context‐dependent process in cancer, functioning as both a tumor‐suppressive and tumor‐promoting mechanism depending on tumor stage, metabolic conditions, therapeutic stress, and the tumor microenvironment. Although modulation of autophagy is a promising strategy to overcome chemoresistance, current therapeutic approaches remain limited by incomplete mechanistic understanding, lack of selectivity, and potential systemic toxicities. The clinical experience with CQ and HCQ highlights both the potential and limitations of nonspecific autophagy inhibition. Future advances will require a shift from broad autophagy inhibition to selective, precision‐based modulation strategies. Greater understanding of selective autophagy pathways, including mitophagy and ER‐phagy, together with biomarker‐guided patient stratification and advanced drug delivery systems, may improve therapeutic efficacy while minimizing toxicity. Ultimately, successful autophagy‐targeted therapy will depend on accurately defining when autophagy should be inhibited, activated, or selectively modulated across distinct tumor contexts. Author Contributions Md Mohiuddin: conceptualization, supervision, writing – review and editing, resources. Md Al Mamun Ahsan: conceptualization, writing – original draft. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The lead author, Md Mohiuddin, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.